Last reviewed · How we verify

Single Dose Group: Belimumab SC 1 x 200 mg

Human Genome Sciences Inc. · Phase 1 active Biologic Quality 0/100

Single Dose Group: Belimumab SC 1 x 200 mg is a Biologic drug developed by Human Genome Sciences Inc.. It is currently in Phase 1 development. Also known as: BENLYSTA™.

At a glance

Generic nameSingle Dose Group: Belimumab SC 1 x 200 mg
Also known asBENLYSTA™
SponsorHuman Genome Sciences Inc.
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Single Dose Group: Belimumab SC 1 x 200 mg

What is Single Dose Group: Belimumab SC 1 x 200 mg?

Single Dose Group: Belimumab SC 1 x 200 mg is a Biologic drug developed by Human Genome Sciences Inc..

Who makes Single Dose Group: Belimumab SC 1 x 200 mg?

Single Dose Group: Belimumab SC 1 x 200 mg is developed by Human Genome Sciences Inc. (see full Human Genome Sciences Inc. pipeline at /company/human-genome-sciences-inc).

Is Single Dose Group: Belimumab SC 1 x 200 mg also known as anything else?

Single Dose Group: Belimumab SC 1 x 200 mg is also known as BENLYSTA™.

What development phase is Single Dose Group: Belimumab SC 1 x 200 mg in?

Single Dose Group: Belimumab SC 1 x 200 mg is in Phase 1.

Related